Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-9809-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CEP55 Monoclonal Antibody (EMRC10-11-55), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody EMRC10-11-55 recognizes the human centrosomal protein (Cep55). Cep55 is a 55 kDa microtubule-bundling protein that is found throughout the cell but specifically localizes to the mitotic spindle during metaphase and the midbody during anaphase. Cep55 is necessary for the completion of cytokenesis, a process that if disregulated promotes tumorigenesis via a mechanism of aneuploidy and chromosomal instablility. Cep55 is downstream of the transcription factor FOXM1, and has been found to be overexpressed in a head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma, breast cancer, colorectal carcinoma (CRC), and in secondary metastatic sites. Expression has been found to correlate with severity of disease and as a cancer biomarker is prognostic of poor outcome in breast cancer. Cep55 is expressed at very modest levels in normal tissue, but is more prominent in testis and thymus. Applications Reported: This EMRC10-11-55 antibody has been reported for use in western blotting and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections. Applications Tested: This EMRC10-11-55 antibody has been tested by immunohistochemistry on FFPE human breast cancer tissue using low pH antigen retrieval at less than or equal to 10 ug/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- EMRC10-11-55
- Vial size
- 25 µg
- Concentration
- 0.5 mg/mL
- Storage
- 4° C
Submitted references The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.
Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma.
Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Wang Q, Greene MI, Hasegawa T, Hirata K, Asaka M, Sato N
Experimental and molecular pathology 2011 Feb;90(1):55-60
Experimental and molecular pathology 2011 Feb;90(1):55-60
Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma.
Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriyama K, Nakazawa E, Harada K, Takasu H, Tamura Y, Kamiguchi K, Asanuma H, Tsuruma T, Terui T, Ishitani K, Ohmura T, Wang Q, Greene MI, Hasegawa T, Hirata K, Sato N
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009 Jun;32(5):474-85
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009 Jun;32(5):474-85
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry on FFPE human breast cancer tissue using 10 µg/mL Mouse IgG1 Isotype Control (left) or 10 µg/mL Anti-Human Cep55 Purified (right) followed by biotinylated Anti-Mouse IgG and DAB visualization.Nuclei are counterstained with hematoxylin.
